Companion Diagnostics Market Size Outlook and Demand Growth Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Companion Diagnostics Market During The Forecast Period 2026–2030?

The companion diagnostics market has experienced substantial growth in its size during recent years. It will grow from $8.69 billion in 2025 to $10.54 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. Historically, this expansion can be attributed to several factors such as the increasing development of targeted cancer therapies, the broadening of oncology clinical trials, greater collaboration between pharmaceutical and diagnostics firms, rising cancer incidence rates, and regulatory approvals for companion tests.

The companion diagnostics market is projected to experience rapid expansion in the coming years. It is forecast to reach $22.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.1%. This anticipated growth is driven by several factors, including the escalating need for personalized treatment options, increased funding in precision medicine initiatives, the expanding scope of immuno-oncology pipelines, the growing integration of AI in diagnostic interpretation, and a heightened regulatory focus on the collaborative development of diagnostics and drugs. Key trends anticipated during this period encompass the wider acceptance of precision oncology diagnostics, the deeper integration of companion diagnostics into the drug development process, the increasing deployment of NGS-based diagnostic platforms, the broadening of biomarker-driven therapeutic approaches, and an intensified commitment to personalized medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

Which Economic Or Industry Drivers Are Impacting The Companion Diagnostics Market?

The growing number of targeted therapies is projected to fuel the expansion of the companion diagnostics market. Targeted therapy is a pharmacological approach that specifically targets distinct characteristics of cancer cells to inhibit disease growth and spread. These medications circulate throughout the body yet exhibit a more precise effect than chemotherapy, often leading to fewer adverse effects. Companion diagnostic testing, based on biological markers, is becoming an essential component of personalized cancer care for targeted cancer therapy. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Therefore, the rise in targeted therapies is driving growth within the companion diagnostics market.

What Market Segments Are Evaluated Within The Companion Diagnostics Market?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

What Industry Trends Are Redefining The Companion Diagnostics Market?

Leading firms within the companion diagnostics market are engaging in joint efforts to create novel therapeutic approaches aimed at advancing personalized medicine, bettering patient results, and maximizing the efficacy of specific treatments. These corporate alliances are set to fast-track the creation and market introduction of companion diagnostics (CDx) for use in hematology and oncology therapies. As an illustration, in January 2024, Agilent Technologies, Inc., a US-based provider of laboratory instruments, software, services, and consumables, revealed a partnership with Incyte, which is a US-based pharmaceutical company. This arrangement combines Agilent’s proficiency and established history in companion diagnostics (CDx) development to aid the growth and market entry of Incyte’s range of hematology and oncology products. Through this joint effort, Agilent can broaden its CDx offerings with additional biomarkers, concurrently, Incyte gains from Agilent’s skill in assay creation, navigating regulatory clearances, and market launch processes to facilitate clinical trials and CDx approval in the U.S. and Europe.

Who Are The Top Market Participants Influencing The Companion Diagnostics Market?

Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems

Read the full companion diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What Are The Top-Performing Regions Within The Companion Diagnostics Market?

North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Companion Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Browse Through More Reports Similar to the Global Companion Diagnostics Market 2026, By The Business Research Company

Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/contact-lenses-global-market-report

Bionic Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/bionic-contact-lenses-global-market-report

Smart Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-contact-lenses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795